Villain, Nicolas

Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group

Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 1,051

Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation

Dubois, B., Villain, N., Schneider, L., Fox, N., Campbell, N., Galasko, D., Kivipelto, M., Jessen, F., Hanseeuw, B., Boada, M., et al. (2024) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 426

Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease

Villain, N., Desgranges, B., Viader, F., de la Sayette, V., Mezenge, F., Landeau, B., Baron, J.-C., Eustache, F., & Chetelat, G. (2008) · Journal of Neuroscience

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 366

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB–PET longitudinal study

Villain, N., Chételat, G., Grassiot, B., Bourgeat, P., Jones, G., Ellis, K. A., Ames, D., Martins, R. N., Eustache, F., Salvado, O., et al. (2012) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 255

Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer’s disease

Villain, N., Fouquet, M., Baron, J.-C., Mezenge, F., Landeau, B., de La Sayette, V., Viader, F., Eustache, F., Desgranges, B., & Chetelat, G. (2010) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 237

New landscape of the diagnosis of Alzheimer’s disease

Frisoni, G. B., Hansson, O., Nichols, E., Garibotto, V., Schindler, S. E., van der Flier, W. M., Jessen, F., Villain, N., Arenaza-Urquijo, E. M., Crivelli, L., et al. (2025) · The Lancet

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 143

Alzheimer's disease including focal presentations

Villain, N., & Dubois, B. (2019) · Seminars in Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 113

High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects

Villain, N., Planche, V., & Levy, R. (2022) · Revue Neurologique

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 87

US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?

Planche, V., & Villain, N. (2021) · JAMA Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 43

Therapeutic news in Alzheimer’s disease: Soon a disease-modifying therapy?

Villain, N. (2022) · Revue Neurologique

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 14